Clinical Trial

The Bridging Antiplatelet Therapy With Cangrelor 2 Study

Study acronym: BIRDGE 2
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-06
Trial Details
NCT Number NCT07225842
Lead Sponsor University of Florida
Conditions Coronary Arterial Disease (CAD)
Enrollment 50 participants
Start Date 2026-02-18
Primary Completion 2027-09 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-05